CVM icon

CEL-SCI Corp

0.2900 USD
+0.0000
0.00%
At close Apr 30, 4:00 PM EDT
After hours
0.2784
-0.0116
4.00%
1 day
0.00%
5 days
-0.96%
1 month
25.87%
3 months
-27.41%
6 months
-67.70%
Year to date
-30.10%
1 year
-80.14%
5 years
-98.35%
10 years
-98.83%
 

About: CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Employees: 44

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

0.67% more ownership

Funds ownership: 9.72% [Q3] → 10.38% (+0.67%) [Q4]

8% less funds holding

Funds holding: 66 [Q3] → 61 (-5) [Q4]

53% less capital invested

Capital invested by funds: $6.32M [Q3] → $2.96M (-$3.36M) [Q4]

59% less call options, than puts

Call options by funds: $40K | Put options by funds: $98K

Research analyst outlook

We haven’t received any recent analyst ratings for CVM.

Financial journalist opinion

Neutral
Business Wire
1 week ago
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to file for Regulatory Approval of Multikine in Saudi Arabia—Pursuing local partnerships to serve Middle East and North Africa Market.
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
Neutral
Business Wire
3 weeks ago
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--New study in the scientific journal “Cancer Cell” supports CEL-SCI's strategy to seek early approval for Multikine.
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
Neutral
Business Wire
1 month ago
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports new data. Treatment with Multikine resulted in up to 95% improvement in Quality of Life for Head and Neck Cancer Patients.
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
Neutral
Business Wire
1 month ago
CEL-SCI Announces Closing of $2.5 Million Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $2.5 million offering .
CEL-SCI Announces Closing of $2.5 Million Offering
Neutral
Business Wire
1 month ago
CEL-SCI Announces Pricing of $2.5 Million Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $2.5 million offering.
CEL-SCI Announces Pricing of $2.5 Million Offering
Neutral
Business Wire
1 month ago
CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Head and Neck Cancer Registration Study Protocol clears FDA review—in talks with potential partners Interested in commercialization of Multikine.
CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
Neutral
Business Wire
1 month ago
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
Neutral
Business Wire
2 months ago
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial.
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
Neutral
Business Wire
2 months ago
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal Q1 2025 financial results: Multikine shows pre-surgical tumor elimination and regression in just 3 weeks.
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
Neutral
Business Wire
3 months ago
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2024 results: set to commence confirmatory study that could bring new standard of care to head & neck cancer.
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
Charts implemented using Lightweight Charts™